

PULMONARY STUDIES SUPPORTED IN 1980 (FOR SAB MEETING, OCTOBER 1980)

EMPHYSEMA/BRONCHITIS RDS/INFLAMMATION DISEASES	EMPHYSEMA/BRONCHITIS CONTINUED	ENVIRONMENTAL (Cigarette Smoke: Active/Passive)	ENVIRONMENTAL CONTINUED	SPECIAL MORPHOLOGICAL SPECIAL FUNCTIONS OF LUNG	IMMUNE MECHANISMS IMMUNOGLOBULIN PRODUCTION: HYPERSENSITIVITY: ALLERGY (CHRONIC BRONCHITIS)	MACROPHAGE STUDIES
I. <u>Proteases: Antiproteases</u>  a. <u>Mechanisms: Biochem (Elastase, α-1AP):</u> 1. Travis/Powers (#1135A) 2. Johnson (#1217R1)  b. <u>Experimental Emphysema: Lung Lesions</u> 1. Weinbaum (#901B) 2. Geokas (#1088A)  c. <u>Susceptibility to COPD in Smokers</u> 1. PPM-Elastase (α2MC/α-1AP, anionic hydrophobic agents) Galdston (#1242R1) 2. <u>Pancreatic Elastase: Circulating Levels (RIA method)</u> α-1AP Geokas (#1088A)  d. <u>Mechanisms: Biochem and Inhibitors of Proteases:</u> 1. <u>Synthetic Inhibitors:</u> Travis/Powers (#1135A)  2. <u>Endogenous Inhibitors (lung)</u> Johnson (#1217R1)  3. <u>Macrophage Protease Inhibitors</u> O'Donnel (#1245)	a. <u>Mechanisms: Inhibitors of 1AP (Cigarette Smoke):</u> 1. Janoff (#1143A) 2. Travis/Powers (#1135A)  II. <u>Purification of Macrophage Elastase</u> O'Donnel (#1245)  III. <u>Elastin Biosynthesis</u> Foster (#1179R2)  IV. <u>Elastin Degradation: (Measurement by RIA)</u> Janoff (#1259)  V. <u>Delivery of Synthetic Protease Inhibitors by Microspheres</u> Liener (#1214)*	I. <u>Human Studies</u> a. <u>Respiratory Disease in Infancy Development of Lung Disease in Adults</u> C. Hall (#1164R2)  b. <u>Pulmonary Function: Adolescents-Parents Pulmonary and Smoking Histories</u> B. van den Berg (#1171R2)  c. <u>Predisposition to COPD</u> M. Galdston (#1242R1)  d. <u>Airway Hyperreactivity (Ozone: Cigarette Smoke)</u> J. Nadel (#1311)  a. <u>Alveolar Clearance Rate of Inert Particles: (Non-Invasive, Magnetic Technique).</u> A. Freedman (#1321)  II. <u>Animal Studies</u> a. <u>Morphological and Metabolic (phospholipids: biochemistry) Cigarette Smoke On Fetal and Perinatal Lung Development and Metabolism (Rat)</u> M. Hamosh (#1308)*	b. <u>Airway Hyperreactivity (Canine): (Ozone: Cigarette Smoke)</u> J. Nadel (#1311)  c. <u>Ozone on Airway Mast Cells Cigarette Smoke (Canine) (On Neurohumoral modulation/histamine release: cyclic AMP/GMP).</u> W. Gold (#1327)	I. <u>Endocrine Functions</u>  a. <u>Endocrine-Like Cells in Airways: (Effects of Hypoxia and CO)</u> Echt (#1244A)  b. <u>APUD CELLS: (Endocrine like cells of lung, and their local neurohormonal control mechanisms)</u> 1. Will (#1036AR2) 2. Kleinerman (#1190)*  c. <u>Metabolic Activities of Pulmonary Endothelium: (Angiotensin I-II: Thromboxanes/Prostaglandins etc.)</u> Ryan (#814BR2)  d. <u>Mast Cells:</u> W. Gold (#1327)	I. <u>Tobacco Antigen</u> Gleich (#1014BR1)  II. <u>Cigarette Smoking and Ig Production: Human Bronchial Lymphocyte.</u> Lawrence (#1215R1)  III. <u>Contractile Proteins: Plasma Membrane (Rabbit)</u> Stossel (#1116A)  IV. <u>Factors in Pulmonary Inflammation</u> Cochrane (#764HR1)	I. <u>Immunological</u>  a. Lawrence (#1215R1) b. Springer (#1307) c. Herscovitz (#1045B) d. Unanue (#1030AR1)  II. <u>Proteases</u>  a. Travis (#1135A) b. Weinbaum (#901B) c. O'Donnel (#1245)  III. <u>Contractile Proteins: Plasma Membrane (Rabbit)</u> Stossel (#1116A)  IV. <u>Factors in Pulmonary Inflammation</u> Cochrane (#764HR1)

TERMINATES/ED

\* 6/30/80

1005045294